Essential medicines

For the list of WHO essential medicines, see WHO Model List of Essential Medicines

Essential medicines, as defined by the World Health Organization (WHO) are "those drugs that satisfy the health care needs of the majority of the population; they should therefore be available at all times in adequate amounts and in appropriate dosage forms, at a price the community can afford."[1]

The WHO has published a model list of essential medicines. Each country is encouraged to prepare their own lists taking into consideration local priorities. Over 150 countries have published an official essential medicines list. The essential medicines list enables health authorities, especially in developing countries, to optimize pharmaceutical resources. The WHO List contains a core list and a complementary list.

The core list presents a list of minimum medicine needs for a basic health care system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment.

The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities are needed. In case of doubt medicines may also be listed as complementary on the basis of higher costs or less attractive cost-effectiveness in a variety of settings. The list is important because: it forms the basis of national drugs policy in many countries, both developed and developing (e.g. South Africa, Eritrea) and governments refer to WHO recommendations when making decisions on health spending.

Theory and practice

The original 1977 WHO definition of "essential medicines" was that they were 'of utmost importance, basic, indispensable, and necessary for the healthcare needs of the population'.[2] The concept was mentioned in one of the ten points of the 1978 Alma Ata Declaration on primary health care.

The difficulty of putting this into practice is reflected in the rather longer and more categorical 2002 definition:

'Essential medicines are those that satisfy the priority health care needs of the population. They are selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness. Essential medicines are intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, and at a price the individual and the community can afford. The implementation of the concept of essential medicines is intended to be flexible and adaptable to many different situations; exactly which medicines are regarded as essential remains a national responsibility.'[3]

The "WHO Model List of Essential Medicines" has been updated every two years since 1977. The current version, the 18th, was published in 2013. The fourth edition of "WHO Model List of Essential Medicines for Children", was also published in 2013.

Cost-to-benefit ratio

Cost effectiveness is the subject of fierce debate between producers (pharmaceutical companies) and purchasers of drugs (national health services).

Number of drugs

The number of drugs has nearly doubled, from the original 186 in 1977 to more 300.[4] The range has increased substantially over the years and now includes an antimigraine drug, antidotes, and antineoplastic drugs. The third list for children from 2011 contains 269 medications.[5]

See also

References

  1. ↑ http://apps.who.int/medicinedocs/en/d/Js4875e/5.2.html
  2. ↑ WHO | Health topics | Essential Medicines who.int.
  3. ↑ WHO | Health topics | Essential Medicines who.int
  4. ↑ Skorton, Madelon L. Finkel, editor ; foreword by David J. (2011). Public health in the 21st century. Santa Barbara, Calif.: Praeger. p. 110. ISBN 9780313375477.
  5. ↑ Bansal, D; Purohit, VK (January 2013). "Accessibility and use of essential medicines in health care: Current progress and challenges in India.". Journal of pharmacology & pharmacotherapeutics 4 (1): 13–8. doi:10.4103/0976-500X.107642. PMID 23662019.

External links